ALM
MCID: ACR014
MIFTS: 52

Acral Lentiginous Melanoma (ALM)

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

MalaCards integrated aliases for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 12 20 15
Acral Lentiginous Malignant Melanoma of Skin 20
Acral Lentiginous Melanoma, Malignant 12
Malignant Acral Lentiginous Melanoma 12
Acral Lentiginous Malignant Melanoma 71
Palmar/plantar Melanoma 20
Subungual Melanoma 20
Alm 20

Classifications:



External Ids:

Disease Ontology 12 DOID:6367
UMLS 71 C0346037

Summaries for Acral Lentiginous Melanoma

GARD : 20 Acral lentiginous melanoma (ALM) is a type of melanoma that occurs on the palms of the hands or the soles of the feet. The condition can develop in normal-appearing skin or within an existing mole. ALM begins as a flat patch of discolored skin that may enlarge slowly over time. Although the cancer cells often remain contained at the skins surface (epidermis) initially, ALM can become invasive and spread as the condition advances. Like other flat forms of melanoma, it can be recognized by the ABCDE rule. Although ALM affects men and women of all skin colors equally, is it most commonly diagnosed in people over age 40. The underlying cause of ALM is poorly understood. It is not related to sun exposure like other forms of skin cancer. Initial treatment generally consists of surgery to remove the skin lesion. Additional therapy (such as radiation therapy or immunotherapy) may then be recommended depending on the severity of the condition.

MalaCards based summary : Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to lentigines and mucosal melanoma, and has symptoms including macule An important gene associated with Acral Lentiginous Melanoma is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sunitinib and Pembrolizumab have been mentioned in the context of this disorder. Affiliated tissues include skin and lymph node, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

Wikipedia : 74 Melanoma is a group of serious skin cancers that arise from pigment cells (melanocytes); acral... more...

Related Diseases for Acral Lentiginous Melanoma

Diseases related to Acral Lentiginous Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 lentigines 30.9 MC1R BRAF
2 mucosal melanoma 30.3 TERT NRAS KIT CDKN2A CD274 BRAF
3 amelanotic melanoma 30.2 VIM KIT BRAF
4 spitz nevus 30.1 HRAS CDKN2A BRAF
5 spindle cell sarcoma 30.0 VIM MUC1 KIT
6 nodular malignant melanoma 30.0 NRAS MC1R KIT HRAS CDKN2A BRAF
7 squamous cell carcinoma 29.5 PTEN MUC1 HRAS CDKN2A BRAF
8 melanoma, cutaneous malignant 1 29.1 TERT PTEN NRAS MC1R KIT HRAS
9 sarcoma 29.0 VIM NRAS MUC1 KIT HRAS BRAF
10 basal cell carcinoma 28.9 TERT PTEN MUC1 MC1R KIT IL10
11 myeloma, multiple 28.9 PTEN NRAS KIT IL10 HRAS CDKN2A
12 skin carcinoma 28.8 TERT PTEN NRAS MC1R KIT IL10
13 skin melanoma 28.8 TERT PTEN NRAS MET MC1R KIT
14 leukemia, acute myeloid 28.6 TERT PTEN NRAS KIT IL10 HRAS
15 melanoma 28.5 VIM TERT PTEN NRAS MET MC1R
16 alstrom syndrome 10.7
17 superficial spreading melanoma 10.5
18 cervical adenoid cystic carcinoma 10.4 KIT CDKN2A
19 bowenoid papulosis 10.4 TERT CDKN2A
20 laryngeal small cell carcinoma 10.4 KIT CDKN2A
21 cecal benign neoplasm 10.4 TERT CDKN2A
22 maxillary sinus benign neoplasm 10.4 KIT CDKN2A
23 cecum adenoma 10.4 TERT CDKN2A
24 lentigo maligna melanoma 10.4
25 vulvar seborrheic keratosis 10.4 PTEN CDKN2A
26 trachea carcinoma 10.4 KIT CD274
27 human papillomavirus infectious disease 10.4 TERT CDKN2A
28 histiocytic sarcoma 10.3 PTEN CDKN2A
29 thyroid tumor 10.3 TERT BRAF
30 primary cutaneous diffuse large b-cell lymphoma, leg type 10.3 CDKN2A CD274
31 mucinous stomach adenocarcinoma 10.3 PTEN KIT
32 serrated polyposis syndrome 10.3 PTEN BRAF
33 seizures, scoliosis, and macrocephaly/microcephaly syndrome 10.3
34 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.3
35 dermatophytosis 10.3
36 reticular perineurioma 10.2 MUC1 KIT
37 axillary lipoma 10.2 MUC1 KIT
38 melphalan allergy 10.2 NRAS CD274 BRAF
39 cystic teratoma 10.2 PTEN KIT CDKN2A
40 teratoma 10.2 PTEN KIT CDKN2A
41 primary cutaneous b-cell lymphoma 10.2 PTEN CDKN2A
42 follicular dendritic cell sarcoma 10.2 KIT CDKN2A CD274
43 malignant peritoneal mesothelioma 10.2 MUC1 CDKN2A
44 vulvar eccrine porocarcinoma 10.2 MUC1 CDKN2A
45 gliomatosis cerebri 10.2 PTEN CDKN2A BRAF
46 kala-azar 1 10.2
47 leishmaniasis 10.2
48 tall cell variant papillary carcinoma 10.2 TERT MET BRAF
49 mixed oligodendroglioma-astrocytoma 10.2 TERT PTEN CD274
50 testicular gonadoblastoma 10.2 VIM KIT

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to Acral Lentiginous Melanoma

Symptoms & Phenotypes for Acral Lentiginous Melanoma

UMLS symptoms related to Acral Lentiginous Melanoma:


macule

GenomeRNAi Phenotypes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

26 (show all 44)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 9.97 MET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.97 IL10
3 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.97 CD274
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.97 VIM
5 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.97 MET
6 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.97 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-119 9.97 MET
8 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.97 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.97 IL10 KIT
10 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.97 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.97 IL10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.97 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.97 VIM
14 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.97 CD274
15 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.97 MET
16 Increased shRNA abundance (Z-score > 2) GR00366-A-187 9.97 CD274
17 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.97 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.97 MET
19 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.97 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.97 MET
21 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.97 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.97 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.97 CD274
24 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.97 CD274 KIT
25 Increased shRNA abundance (Z-score > 2) GR00366-A-38 9.97 MET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.97 MET
27 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.97 IL10
28 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.97 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.97 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.97 MET VIM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.97 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.97 IL10
33 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.97 IL10
34 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.97 MET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.97 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.97 CD274 IL10 KIT MET
37 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.97 KIT
38 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.97 KIT
39 Decreased substrate adherent cell growth GR00193-A-1 9.56 KIT MET
40 Decreased substrate adherent cell growth GR00193-A-2 9.56 KIT
41 Decreased substrate adherent cell growth GR00193-A-3 9.56 BRAF MET
42 Decreased substrate adherent cell growth GR00193-A-4 9.56 BRAF KIT MET
43 Decreased cell migration GR00055-A-1 9.46 MET VIM
44 Decreased cell migration GR00055-A-3 9.46 BRAF HRAS

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.38 BRAF CD274 CDKN2A CSPG4 HLA-G HRAS
2 cellular MP:0005384 10.37 BRAF CD274 CDKN2A CSPG4 IL10 KIT
3 behavior/neurological MP:0005386 10.34 BRAF CD274 CDKN2A HRAS IL10 KIT
4 immune system MP:0005387 10.34 BRAF CD274 CDKN2A CSPG4 HLA-G IL10
5 hematopoietic system MP:0005397 10.33 BRAF CD274 CDKN2A CSPG4 HLA-G IL10
6 digestive/alimentary MP:0005381 10.23 BRAF CDKN2A HRAS IL10 KIT MET
7 endocrine/exocrine gland MP:0005379 10.21 BRAF CDKN2A HRAS IL10 KIT MET
8 embryo MP:0005380 10.17 BRAF CDKN2A IL10 KIT MET NRAS
9 integument MP:0010771 10.16 BRAF CD274 CDKN2A HRAS IL10 KIT
10 craniofacial MP:0005382 10.13 BRAF HRAS IL10 KIT MC1R MET
11 liver/biliary system MP:0005370 10.13 BRAF CDKN2A CSPG4 IL10 KIT MET
12 neoplasm MP:0002006 10.13 BRAF CDKN2A HRAS IL10 KIT MC1R
13 nervous system MP:0003631 10.1 BRAF CDKN2A CSPG4 HRAS IL10 KIT
14 muscle MP:0005369 10.06 BRAF CDKN2A HRAS IL10 KIT MET
15 limbs/digits/tail MP:0005371 10.04 BRAF IL10 KIT MC1R MET NRAS
16 no phenotypic analysis MP:0003012 10.02 CD274 CDKN2A CSPG4 HRAS IL10 KIT
17 normal MP:0002873 10.02 BRAF CSPG4 HRAS IL10 KIT MET
18 respiratory system MP:0005388 9.81 BRAF CDKN2A HRAS IL10 KIT MET
19 pigmentation MP:0001186 9.73 BRAF CDKN2A KIT MC1R NRAS PTEN
20 skeleton MP:0005390 9.61 BRAF CD274 CDKN2A HRAS IL10 KIT
21 vision/eye MP:0005391 9.23 BRAF CDKN2A IL10 KIT MET NRAS

Drugs & Therapeutics for Acral Lentiginous Melanoma

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
2
Pembrolizumab Approved Phase 2 1374853-91-4
3
Ipilimumab Approved Phase 2 477202-00-9
4
nivolumab Approved Phase 2 946414-94-4
5
Cediranib Investigational Phase 2 288383-20-0 9933475
6
Maleic acid Experimental Phase 2 110-16-7 444266
7 Protein Kinase Inhibitors Phase 2
8 Imatinib Mesylate Phase 2 220127-57-1 123596
9 Angiogenesis Inhibitors Phase 2
10 Immunoglobulins Phase 2
11 Antibodies, Monoclonal Phase 2
12 Antibodies Phase 2
13 Antineoplastic Agents, Immunological Phase 2
14
Ganciclovir Approved, Investigational Phase 1 82410-32-0 3454
15 Anti-Infective Agents Phase 1
16 Antiviral Agents Phase 1
17 Ganciclovir triphosphate Phase 1

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Phase II Study of AZD2171 in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma Completed NCT00243061 Phase 2 cediranib maleate
2 A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT Completed NCT00470470 Phase 2 imatinib mesylate
3 A Phase II Study of Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma and Melanomas That Arise on Chronically Sun Damaged Skin. Completed NCT00424515 Phase 2 Imatinib
4 A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma Completed NCT00577382 Phase 2 Sunitinib
5 An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma Recruiting NCT02875132 Phase 2 pembrolizumab
6 A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma Recruiting NCT03698019 Phase 2
7 A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Recruiting NCT04511013 Phase 2 Binimetinib;Encorafenib
8 A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy Active, not recruiting NCT02978443 Phase 2 Nivolumab;Ipilimumab
9 A Phase II Trial of SCH 727965 (NSC 747135) in Patients With Stage IV Melanoma Active, not recruiting NCT00937937 Phase 2 Dinaciclib
10 Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma Terminated NCT01120275 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
11 A Phase I Study of Intralesional Administration of an Adenovirus Vector Expressing the HSV-1 Thymidine Kinase Gene (AdV.RSV-TK) in Combination With Escalating Doses of Ganciclovir in Patients With Cutaneous Metastatic Malignant Melanoma Completed NCT00005057 Phase 1 ganciclovir
12 A Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD) Recruiting NCT03025256 Phase 1
13 Melanoma Family Case-Control Study Protocol Unknown status NCT00445783

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

Anatomical Context for Acral Lentiginous Melanoma

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

40
Skin, Lymph Node

Publications for Acral Lentiginous Melanoma

Articles related to Acral Lentiginous Melanoma:

(show top 50) (show all 683)
# Title Authors PMID Year
1
Melanocytic Hyperactivation Simulating an Acral Lentiginous Melanoma in a Patient With Parkinson Disease Treated by Levodopa. 61
33595233 2021
2
Clinical features of subungual melanoma according to the extent of Hutchinson's nail sign: a retrospective single-centre study. 61
32562580 2021
3
Extensive Perineural Spread of Subungual Melanoma. 61
32916345 2021
4
Racial and ethnic differences in the clinical presentation and outcomes of acral lentiginous melanoma. 61
32683697 2021
5
Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease. 61
32330367 2021
6
Subungual melanoma in situ in a 21-year-old man: How to manage a patient with longitudinal melanonychia from infant? 61
32614068 2021
7
Regional lymph node infiltration and thick lesions are associated with poor prognosis in high-risk resected melanomas: A retrospective cohort study. 61
33456772 2021
8
Immunohistochemical study of CD117 in various cutaneous melanocytic lesions. 61
33363589 2021
9
Subungual Melanocytic Lesions: Key Clinical and Pathologic Concepts and Biopsy Techniques. 61
33465340 2021
10
Dermatoscopy of melanoma according to type, anatomic site and stage: a 2020 update. 61
33314891 2020
11
Subtyping Cutaneous Melanoma Matters. 61
33409460 2020
12
Surgical procedures in melanoma in 2020: recommended deep and lateral margins, indications for sentinel lymph node biopsy, and complete lymph node dissection. 61
33314890 2020
13
The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. 61
32529271 2020
14
Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. 61
33290520 2020
15
Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma. 61
32516238 2020
16
Does acral lentiginous melanoma subtype account for differences in patterns of care in Black patients? 61
33461732 2020
17
Acral lentiginous melanoma: clinicopathological characteristics and survival outcomes in the US National Cancer Database 2004-2016. 61
32407556 2020
18
Acral lentiginous melanoma in situ: dermoscopic features and management strategy. 61
33239715 2020
19
The first Chinese case of pediatric subungual melanoma: A case report and literature review. 61
32594641 2020
20
Acral lentiginous melanoma: Clinicopathologic and survival differences according to tumour location. 61
32363586 2020
21
TERT amplification but not activation of canonical Wnt/β-catenin pathway is involved in acral lentiginous melanoma progression to metastasis. 61
32404956 2020
22
Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. 61
33053175 2020
23
Clinicopathological, immunohistochemical and fluorescence in-situ hybridisation features of early subungual melanoma: an analysis of 65 cases. 61
33065755 2020
24
MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project. 61
32898390 2020
25
Acral lentiginous melanoma: A retrospective study. 61
32979858 2020
26
Clinical and Demographic Profile of Cutaneous Melanoma: Pakistani Perspective. 61
33330006 2020
27
PD-1 blockade in Japanese patients with acral lentiginous melanoma. 61
32622883 2020
28
Acral lentiginous melanoma: a single-centre retrospective review of four decades in East-Central Europe. 61
31989672 2020
29
Clinical and histological characteristics, and management of melanoma in French Guiana, 2007-2018. 61
32506532 2020
30
Augmented decision-making for acral lentiginous melanoma detection using deep convolutional neural networks. 61
31919901 2020
31
Dermoscopic diagnosis of subungual hematoma: new observations. 61
32994768 2020
32
Prognostic significance of acral lentiginous histologic type in T1 melanoma. 61
32759976 2020
33
Pediatric nail disorders: a review. 61
32692049 2020
34
Assessment of internet sources on subungual melanoma. 61
30169432 2020
35
Use of magnetic resonance imaging as a noninvasive technique to identify acral lentiginous melanoma. 61
31560976 2020
36
Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance. 61
32515086 2020
37
Treatments and associated outcomes of acral lentiginous melanoma: A review. 61
31738961 2020
38
Skin Cancer Awareness Among 1 271 Black Africans in South Africa. 61
31841225 2020
39
Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry. 61
32208196 2020
40
Acquired agminated melanocytic nevus in the acral area is a potential mimicker of acral lentiginous melanoma: A three-case series report and published work review. 61
32363624 2020
41
Acral Lentiginous Melanoma: A Rare Variant With Unique Diagnostic Challenges. 61
32642340 2020
42
National Comprehensive Analysis of Characteristics of Acral Lentiginous Melanoma. 61
32487638 2020
43
Mutation profile of primary subungual melanomas in Caucasians. 61
32637031 2020
44
IMP dehydrogenase rod/ring structures in acral melanomas. 61
31883196 2020
45
Quality and Readability of Online Health Information for Acral Lentiginous Melanoma. 61
32483094 2020
46
Subungual melanoma: the experience of a Greek melanoma reference centre from 2003 to 2018. 61
31944385 2020
47
A retrospective study of malignant melanoma from a tertiary care centre in Saudi Arabia from 2004 to 2016. 61
31256363 2020
48
BRAF, KIT, and NRAS Mutations of Acral Melanoma in White Patients. 61
32017841 2020
49
Intratumor Heterogeneity of KIT Gene Mutations in Acral Lentiginous Melanoma. 61
31393283 2020
50
Acral lentiginous melanoma: differences in survival compared with other subtypes. 61
31628856 2020

Variations for Acral Lentiginous Melanoma

Cosmic variations for Acral Lentiginous Melanoma:

9 (show top 50) (show all 415)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149751249 SETD2 skin,subungual,malignant melanoma,acral lentiginous c.242C>G p.S81C 3:47113999-47113999 16
2 COSM103038750 SETD2 skin,subungual,malignant melanoma,acral lentiginous c.4592C>G p.S1531C 3:47113999-47113999 16
3 COSM96844153 PTEN skin,acral,malignant melanoma,acral lentiginous c.333G>A p.W111* 10:87933092-87933092 16
4 COSM87132454 PIK3CA skin,subungual,malignant melanoma,acral lentiginous c.3140A>T p.H1047L 3:179234297-179234297 16
5 COSM87153575 PIK3CA skin,subungual,malignant melanoma,acral lentiginous c.688C>T p.R230* 3:179201415-179201415 16
6 COSM148953047 PIK3CA skin,subungual,malignant melanoma,acral lentiginous c.688C>T p.R230* 3:179201415-179201415 16
7 COSM148932862 PIK3CA skin,subungual,malignant melanoma,acral lentiginous c.*220A>T p.? 3:179234297-179234297 16
8 COSM110841965 PIK3C2G skin,subungual,malignant melanoma,acral lentiginous c.2381G>A p.W794* 12:18424039-18424039 16
9 COSM132942009 PIK3C2G skin,subungual,malignant melanoma,acral lentiginous c.2504G>A p.W835* 12:18424039-18424039 16
10 COSM86283911 PIK3C2G skin,subungual,malignant melanoma,acral lentiginous c.2381G>A p.W794* 12:18424039-18424039 16
11 COSM97107359 NRAS skin,acral,malignant melanoma,acral lentiginous c.182A>G p.Q61R 1:114713908-114713908 16
12 COSM97107724 NRAS skin,acral,malignant melanoma,acral lentiginous c.34G>T p.G12C 1:114716127-114716127 16
13 COSM87699062 NOTCH1 skin,subungual,malignant melanoma,acral lentiginous c.5828C>T p.A1943V 9:136500658-136500658 16
14 COSM127363793 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.445C>A p.H149N 1:45331214-45331214 16
15 COSM93155822 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1363C>A p.H455N 1:45331214-45331214 16
16 COSM112178529 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1360C>A p.H454N 1:45331214-45331214 16
17 COSM126982106 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.116-1777C>A p.? 1:45331214-45331214 16
18 COSM97247468 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1435C>A p.H479N 1:45331214-45331214 16
19 COSM97277083 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1402C>A p.H468N 1:45331214-45331214 16
20 COSM113994737 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1444C>A p.H482N 1:45331214-45331214 16
21 COSM91745953 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1360C>A p.H454N 1:45331214-45331214 16
22 COSM97257170 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1360C>A p.H454N 1:45331214-45331214 16
23 COSM114250224 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1393C>A p.H465N 1:45331214-45331214 16
24 COSM97269116 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1405C>A p.H469N 1:45331214-45331214 16
25 COSM129783708 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.1402C>A p.H468N 1:45331214-45331214 16
26 COSM119808750 MUTYH skin,subungual,malignant melanoma,acral lentiginous c.445C>A p.H149N 1:45331214-45331214 16
27 COSM85771003 MSH6 skin,subungual,malignant melanoma,acral lentiginous c.3731T>A p.L1244* 2:47806288-47806288 16
28 COSM144450610 MSH6 skin,subungual,malignant melanoma,acral lentiginous c.2825T>A p.L942* 2:47806288-47806288 16
29 COSM132091399 MSH6 skin,subungual,malignant melanoma,acral lentiginous c.3341T>A p.L1114* 2:47806288-47806288 16
30 COSM144632561 MSH6 skin,subungual,malignant melanoma,acral lentiginous c.635T>A p.L212* 2:47806288-47806288 16
31 COSM131462784 MSH6 skin,subungual,malignant melanoma,acral lentiginous c.2825T>A p.L942* 2:47806288-47806288 16
32 COSM88313315 KIT skin,subungual,malignant melanoma,acral lentiginous c.1924A>G p.K642E 4:54728055-54728055 16
33 COSM88319109 KIT skin,acral,malignant melanoma,acral lentiginous c.2468A>G p.Y823C 4:54733176-54733176 16
34 COSM88317916 KIT skin,acral,malignant melanoma,acral lentiginous c.1715A>G p.D572G 4:54727483-54727483 16
35 COSM88317455 KIT skin,acral,malignant melanoma,acral lentiginous c.1733A>G p.Y578C 4:54727501-54727501 16
36 COSM88317449 KIT skin,acral,malignant melanoma,acral lentiginous c.1658A>C p.Y553S 4:54727426-54727426 16
37 COSM88312858 KIT skin,acral,malignant melanoma,acral lentiginous c.1679T>A p.V560D 4:54727447-54727447 16
38 COSM88321603 KIT skin,acral,malignant melanoma,acral lentiginous c.1965T>G p.N655K 4:54728096-54728096 16
39 COSM106228118 FBXO11 skin,subungual,malignant melanoma,acral lentiginous c.169+1907A>T p.? 2:47806288-47806288 16
40 COSM132221843 ERBB3 skin,subungual,malignant melanoma,acral lentiginous c.518G>C p.G173A 12:56100202-56100202 16
41 COSM105935149 ERBB3 skin,subungual,malignant melanoma,acral lentiginous c.2981G>C p.G994A 12:56100202-56100202 16
42 COSM133019558 ERBB3 skin,subungual,malignant melanoma,acral lentiginous c.881G>C p.G294A 12:56100202-56100202 16
43 COSM86588492 ERBB3 skin,subungual,malignant melanoma,acral lentiginous c.3158G>C p.G1053A 12:56100202-56100202 16
44 COSM118787231 BRAF skin,acral,malignant melanoma,acral lentiginous c.1799T>A p.V600E 7:140753336-140753336 16
45 COSM149388790 BRAF skin,acral,malignant melanoma,acral lentiginous c.1526G>C p.G509A 7:140781602-140781602 16
46 COSM88806239 BRAF skin,acral,malignant melanoma,acral lentiginous c.1526G>C p.G509A 7:140781602-140781602 16
47 COSM118790474 BRAF skin,acral,malignant melanoma,acral lentiginous c.1406G>C p.G469A 7:140781602-140781602 16
48 COSM150565545 BRAF skin,acral,malignant melanoma,acral lentiginous c.1406G>C p.G469A 7:140781602-140781602 16
49 COSM142536758 BARD1 skin,subungual,malignant melanoma,acral lentiginous c.159-28087C>T p.? 2:214780642-214780642 16
50 COSM143153704 BARD1 skin,subungual,malignant melanoma,acral lentiginous c.215+16419C>T p.? 2:214780642-214780642 16

Expression for Acral Lentiginous Melanoma

Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for Acral Lentiginous Melanoma

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 VIM PTEN NRAS MUC1 MET KIT
2
Show member pathways
13.73 VIM PTEN NRAS MUC1 MET KIT
3
Show member pathways
13.42 PTEN NRAS MET KIT HRAS HLA-G
4
Show member pathways
13.26 PTEN NRAS MET KIT IL10 HRAS
5
Show member pathways
13.24 VIM NRAS MET KIT HRAS BRAF
6
Show member pathways
13.17 VIM NRAS MUC1 MET KIT IL10
7
Show member pathways
13.03 PTEN NRAS MET KIT HRAS BRAF
8
Show member pathways
12.89 TERT PTEN NRAS MET KIT HRAS
9
Show member pathways
12.87 PTEN NRAS MET HRAS BRAF
10
Show member pathways
12.86 PTEN NRAS MET HRAS BRAF
11
Show member pathways
12.85 NRAS MC1R KIT HRAS CDKN2A BRAF
12
Show member pathways
12.8 NRAS MET KIT HRAS BRAF
13
Show member pathways
12.8 PTEN NRAS KIT HRAS CDKN2A BRAF
14 12.74 NRAS MET KIT HRAS BRAF
15
Show member pathways
12.71 NRAS MET KIT HRAS BRAF
16
Show member pathways
12.7 PTEN NRAS MET KIT HRAS
17
Show member pathways
12.68 PTEN NRAS MET HRAS BRAF
18
Show member pathways
12.6 PTEN NRAS MET HRAS CDKN2A BRAF
19
Show member pathways
12.59 PTEN NRAS MET HRAS BRAF
20
Show member pathways
12.51 VIM PTEN NRAS IL10 HRAS CD274
21
Show member pathways
12.48 NRAS HRAS HLA-G BRAF
22
Show member pathways
12.47 PTEN NRAS MUC1 HRAS
23
Show member pathways
12.46 PTEN NRAS MET HRAS BRAF
24 12.43 VIM PTEN NRAS MET HRAS CDKN2A
25
Show member pathways
12.4 NRAS IL10 HRAS BRAF
26
Show member pathways
12.38 PTEN NRAS HRAS BRAF
27
Show member pathways
12.38 NRAS MET KIT HRAS BRAF
28
Show member pathways
12.32 NRAS MUC1 HRAS BRAF
29 12.29 NRAS MET HRAS BRAF
30 12.28 NRAS HRAS HLA-G CDKN2A
31 12.28 TERT PTEN NRAS MET KIT HRAS
32
Show member pathways
12.24 TERT MET KIT IL10 HLA-G
33
Show member pathways
12.21 PTEN NRAS MET HRAS BRAF
34 12.07 PTEN NRAS HRAS HLA-G CDKN2A
35 12.07 TERT PTEN NRAS HRAS HLA-G CDKN2A
36 11.97 PTEN NRAS HRAS
37
Show member pathways
11.97 PTEN NRAS IL10 HRAS BRAF
38 11.96 NRAS HRAS BRAF
39 11.95 VIM MUC1 IL10
40 11.95 PTEN NRAS HRAS CDKN2A
41 11.94 NRAS HRAS BRAF
42
Show member pathways
11.93 NRAS HRAS BRAF
43 11.89 PTEN HRAS CDKN2A BRAF
44
Show member pathways
11.89 TERT PTEN NRAS MET KIT HRAS
45
Show member pathways
11.77 NRAS KIT HRAS BRAF
46 11.76 PTEN NRAS HRAS CDKN2A BRAF
47 11.72 NRAS HRAS BRAF
48 11.7 NRAS HRAS CDKN2A BRAF
49
Show member pathways
11.67 NRAS HRAS BRAF
50 11.63 NRAS HRAS BRAF

GO Terms for Acral Lentiginous Melanoma

Cellular components related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.44 VIM TERT PTEN NRAS MUC1 MET

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.81 VIM MUC1 KIT IL10
2 signal transduction GO:0007165 9.81 NRAS MET MC1R KIT IL10 HRAS
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.73 NRAS MUC1 HRAS
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.71 PTEN KIT IL10
5 regulation of protein stability GO:0031647 9.67 TERT PTEN CDKN2A
6 Ras protein signal transduction GO:0007265 9.63 NRAS HRAS CDKN2A
7 negative regulation of neuron apoptotic process GO:0043524 9.56 TERT IL10 HRAS BRAF
8 replicative senescence GO:0090399 9.55 TERT CDKN2A
9 negative regulation of T cell proliferation GO:0042130 9.54 IL10 HLA-G CD274
10 positive regulation of phospholipase C activity GO:0010863 9.52 KIT HRAS
11 negative regulation of endothelial cell apoptotic process GO:2000352 9.5 TERT IL10 BRAF
12 somatic stem cell division GO:0048103 9.48 KIT CDKN2A
13 regulation of axon regeneration GO:0048679 9.43 PTEN BRAF
14 myeloid progenitor cell differentiation GO:0002318 9.4 KIT BRAF
15 MAPK cascade GO:0000165 9.35 NRAS MET KIT HRAS BRAF
16 positive regulation of gene expression GO:0010628 9.1 VIM PTEN KIT HRAS CDKN2A BRAF

Molecular functions related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 VIM TERT PTEN MET HLA-G BRAF

Sources for Acral Lentiginous Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....